... MONTREAL Oct. 6 /- Caprion Proteomics Inc. announced...Under the contract to be performed over a five-year period Caprionwi... We are very pleased to be granted the opportunity to expand ourinfec...Caprion will retain rights to commercialize candidate biomarkers andd...

MONTREAL, Oct. 6 /PRNewswire/ -- Caprion Proteomics Inc. announced
today that it has been awarded a $12.9 million contract by the National
Institute of Allergy and Infectious Diseases (NIAID), a part of the US
National Institutes of Health, to carry out Biodefense research in the area
of infectious disease biomarkers.

Under the contract to be performed over a five-year period, Caprion
will act as one of two NIAID Clinical Proteomics Centers for Infectious
Disease & Biodefense, and will employ its distinctive CellCarta(R)
quantitative protein profiling technologies to perform several large scale
applied proteomics projects using human clinical samples from patients with
infectious diseases. The projects will be aimed at the discovery,
qualification, and verification of candidate biomarkers with potential for
clinical use to improve detection and diagnosis and to monitor therapeutic
and vaccine responses and susceptibility to infection for diseases caused
by various pathogens. This second major Biodefense research contract
awarded to Caprion by NIAID builds on the expertise and results
demonstrated by Caprion as part of an initial contract awarded in 2004 and
still in progress.

"We are very pleased to be granted the opportunity to expand our
infectious disease research program with NIAID into the area of clinical
biomarker discovery and validation," said Martin LeBlanc, President and CEO
at Caprion. "This second major contract award from the NIAID provides
further evidence of Caprion's solid scientific capabilities and industry
leadership position as a proteomics and biomarker services provider."

Caprion will retain rights to commercialize candidate biomarkers and
diagnostic products discovered in this project.

About Caprion Proteomics, Inc.

Caprion Proteomics is the leading provider of proteomics based services
to the pharmaceutical industry. Caprion's proprietary proteomics discovery
technology, CellCarta(R), is a gel-free, label-free mass spectrometry
platform that enables a comprehensive, quantitative and robust measurement
of the protein expression differences across large sets of biological
samples. Caprion has been providing biomarker and target identification
services since 2002, and has served such clients as Pfizer, Johnson &
Johnson, Abbott Laboratories, Biogen Idec, Daiichi-Sankyo,
Mitsubishi-Tanabe, Wyeth, AstraZeneca, Merck, Boehringer Ingelheim, ICOS,
Bayer-Schering, EMD-Serono, Vertex, DebioPharm and Transgene. Caprion also
has been awarded two major 5-year Biodefense proteomics research contracts
in infectious disease with the NIH-NIAID. For more information, please
visit: http://www.caprion.com.

(Date:12/8/2016)... , Dec. 8, 2016 Anaconda BioMed S.L., a ... of the next generation neuro-thrombectomy system for the treatment ... Tudor G. Jovin, MD to join its Scientific Advisory ... a strategic network of scientific and clinical experts to ... of the ANCD BRAIN ® to its clinical ...

(Date:6/21/2016)... British Columbia , June 21, 2016 /PRNewswire/ ... appointed to the new role of principal product ... been named the director of customer development. Both ... NuData,s chief technical officer. The moves reflect NuData,s ... teams in response to high customer demand and ...